Key Points
German biopharma outfit BioNTech SE reported lackluster fiscal Q4 results on Tuesday.
Guidance for the year now underway is just as disappointing.
The creators of this company’s breakthrough science used in one of only a handful of approved COVID-19 vaccines are leaving BioNTech to support a new biopharma venture.
- 10 stocks we like better than BioNTech Se ›
Last quarter's reported loss isn't the problem. Although it was slightly bigger than expected, the analyst community knew the company would likely remain in the red due to a revenue headwind for the quarter in question.
Rather, the chief problem for BioNTech SE (NASDAQ: BNTX) shareholders today is disappointing guidance for the fiscal year now underway, and news that this biopharma outfit's co-founders are planning to turn their attention on a new biopharma company to be formed by the end of this year. Investors understandably panicked, sending BNTX shares 20.9% lower as of 11:47 a.m. ET Tuesday.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
A bevy of bad news
For the fiscal fourth quarter ending in December, Germany-based BioNTech turned €907.4 million in revenue into an adjusted per-share loss of €0.33. Both were down from year-ago comparisons, when demand for its COVID-19 vaccine was stronger. And, while sales topped analysts' estimates, earnings fell short of the expected loss of only €0.21 per share.
Image source: Getty Images.
The foreseeable future isn't looking any more encouraging either. For the entirety of fiscal 2026, BioNTech expects revenue to roll in between €2.0 billion and €2.3 billion, down from 2025's top line of nearly €2.9 billion, as well as below analysts' sales projections.
Moreover, the impending loss of this company's co-founders' involvement could prove to be a stumbling block. Uğur Şahin and Özlem Türeci -- who helped develop an mRNA-based COVID-19 vaccine -- now intend to support a new company's R&D that will focus on the further development of mRNA-based therapies while BioNTech continues to work on its own pipeline that includes a handful of late-stage oncology drugs.
Already more than priced in
The knee-jerk response is understandable. Founder involvement is often crucial to a company's success, particularly when that organization is still in its infancy. BioNTech's lackluster full-year revenue guidance also caught investors off guard.
What's largely being overlooked in today's bearish thinking, however, is that most (if not all) of this bad news already seems to be reflected in the stock's price. While it still brings above-average risk to the table, today's new 52-week low is arguably more of a buying opportunity than a warning for anyone who can stomach such risk.
Should you buy stock in BioNTech Se right now?
Before you buy stock in BioNTech Se, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioNTech Se wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $530,233!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,682!*
Now, it’s worth noting Stock Advisor’s total average return is 955% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 10, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
